AstraZeneca and Oracle Partner on AI for Clinical Trials
Oct 20, 2026
Healthcare
Cantex and Headlamp Partner to Advance Azeliragon for MS Depression and Fatigue
May 14, 2026
Cantex Pharmaceuticals and Headlamp Health have announced a partnership to use Headlamp's Lumos AI platform to accelerate the development of azeliragon for treating severe depression and fatigue in multiple sclerosis patients.
Cantex Pharmaceuticals and Headlamp Health announced in a press release a collaboration to apply Headlamp's Lumos AI platform to the clinical development of azeliragon for severe depression and fatigue in patients with multiple sclerosis.
Headlamp's Lumos AI is a neuro symbolic, multi agent platform designed for neuropsychiatric drug development. It integrates biological, behavioral, biomarker, and clinical data into a unified intelligence layer, helping teams identify responder and non responder subtypes earlier and refine trial design.
Under the agreement, Headlamp Health will deploy Lumos AI to analyze data across azeliragon's development program. Azeliragon is an oral, blood brain barrier penetrant RAGE inhibitor in clinical development, targeting neuroinflammatory processes linked to depression and fatigue in multiple sclerosis patients.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Enterprise AI Brief, Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Enterprise
Nov 13 Nvidia invested in a record 121 startup funding rounds in 2026, Crunchbase data shows Nov 13 KeyBanc survey: AI-native software grows faster but loses more money Nov 13 PangeAI signs Sky Blue Impact to speed up data centre site analysis Nov 13 Druva launches backup and recovery for Copilot Studio AI agents Nov 13 Redesign Health launches growth equity practice for clinical AIMore from Life Sciences
Nov 13 Machine-learning models predict death risk after heart attack better than standard score Nov 13 Redesign Health launches growth equity practice for clinical AI Nov 13 Dyania Health and Nvidia bring clinical reasoning AI inside hospital networks Nov 13 Betterness extends seed round to $3.5M for Miami AI health networks Nov 13 93% of health systems now use AI, CHIME survey findsFree newsletter
Life AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Market report
.png)
2025 Generative AI in Professional Services Report
Thomson Reuters
This report by Thomson Reuters explores the integration and impact of generative AI technologies, such as ChatGPT and Microsoft Copilot, within the professional services sector. It highlights the growing adoption of GenAI tools across industries like legal, tax, accounting, and government, and discusses the challenges and opportunities these technologies present. The report also examines professionals' perceptions of GenAI and the need for strategic integration to maximize its value.
Read moreYou may also like
Azra AI Acquires Blackford Analysis
Oct 20, 2026
Acquisitions
Flagship Pioneering Merges Three Biotech Platforms Into Etcelera
Oct 29, 2026
Healthcare
Laza Medical raises up to $160 million for cardiac imaging system
Nov 04, 2026
Funding
ALLOX Raises $10.5 Million for AI Drug Discovery Platform
Oct 29, 2026
Funding
Helfie AI and Health Innovation South West to Test Smartphone Hypertension Screening
Oct 19, 2026
Healthcare
Free, six days a week
Daily AI Brief: the AI news that matters, in your inbox.